references
TRANSLATION
Once molecules have been identified in the research stage, the suitability of the molecule to become a drug has to be assessed by testing in vitro and in vivo. Optimized leads are further evaluated for their properties, safety, and efficacy in pre-clinical studies before progressing to Phase I clinical trials in healthy human volunteers and to Phase IIa/proof-of-concept studies in patients.
SCYX-7158
HAT
DNDI-0690
LEISHMANIASIS
Therapeutics Ltd, India; SCYNEXIS Inc., USA; Avista Pharma (formerly SCYNEXIS), USA; Swiss Tropical and Public Health Institute, Switzerland; Institute of Tropical Medicine Antwerp, Belgium; Institut de Recherche pour le Développement, France; Institut National de Recherche Biomédicale, DRC
Objective: Develop and register SCYX-7158 as a new drug for the treatment of stage 2 HAT caused by T. b. gambiense, ideally also for stage 1 HAT. Main partners: Anacor Pharmaceuticals Inc., USA; Advinus
Medicine, UK; TB Alliance, USA; Auckland University, New Zealand; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; WuXi AppTech, China; Aptuit, Italy; Accelera, Italy
Objective: Progress the pre-clinical development of DNDi-0690, a selected nitroimidazole for the treatment of VL and possibly CL. Main partners: London School of Hygiene and Tropical
Denmark; SGS, Belgium; PhinC, France; Centres d’Investigation Clinique des Centres Hospitaliers Universitaires de ClermontFerrand, Lille et Bichat-Claude Bernard, France; Cardiabase, France; Optimed, France; UBC, Switzerland; Sanofi-Chinoin, Hungary; Aptuit, Italy
CpG-D35
LEISHMANIASIS
DNDI-6148
LEISHMANIASIS
Fexinidazole-Miltefosine LEISHMANIASIS combination
Objective: Develop an oral-only therapy for the treatment of VL with a combination of fexinidazole and miltefosine. Main partners: Institute of Endemic Disease, Khartoum
Objective: Produce an immunomodulator to stimulate the innate immune system to fight the parasitic infection as an adjunct to drug therapy. Main partners: US Food and Drug Administration, USA;
Objective: Progress the pre-clinical development of DNDI-6148, a selected oxaborole for the treatment of VL. Main partners: Anacor Pharmaceuticals Inc., USA; Syngene,
India; WuXi AppTech, China; Wil Research/Charles River, France; Sara Pharm, Romania; Sandexis, UK; Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Belgium; London School of Hygiene and Tropical Medicine, UK
National Institutes of Health, USA; Ohio State University, USA; Nagasaki University, Japan; University of Osaka, Japan; GeneDesign Inc., Japan
Anfoleish
LEISHMANIASIS
University, Sudan; London School of Hygiene and Tropical Medicine, UK; Kenya Medical Research Institute, Kenya; Koninklijk Instituut voor de Tropen, The Netherlands; Kacheliba District Hospital, Kenya; The Netherlands Cancer Institute, The Netherlands; Makerere University, Uganda; Uppsala University, Sweden; Amudat Hospital, Uganda; Leishmaniasis East Africa Platform; Utrecht University, The Netherlands; BaseCon,
Objective: Develop a topical anti-parasitic treatment containing amphotericin B for the treatment of CL. Main partners: Humax Pharmaceutical, Colombia; Programa
de Estudio y Control de Enfermedades Tropicales, Universidad de Antioquia, Medellin, Colombia
10
• R&D Portfolio
